A cytomegalovirus-based therapeutic vaccine for chronic hepatitis B
Ended Project Grant Awarded Last action
- Award ID
- R44AI129232
- Recipient
-
Tomegavax, Inc. UEI NUE6Q16X2GL1 Part of VIR Biotechnology, Inc.
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,982,523
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date
- Originally
- Place of performance
- Oregon, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $1,000,000 | |
| Amendment | $0 | |
| Amendment | $685,089 | |
| Amendment | $0 | |
| Original award | $297,434 |
Quick answers
Who received award R44AI129232?
R44AI129232 was awarded to Tomegavax, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on March 3, 2017.
How much is award R44AI129232 worth?
$1,982,523 has been obligated on R44AI129232.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award